2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-15778A
    AVE 0991 sodium salt 306288-04-0 99.41%
    AVE 0991 sodium salt is a nonpeptide and orally active Ang-(1-7) receptor Mas agonist. AVE 0991 competes for high-affinity binding of [125I]-Ang-(1-7) to bovine aortic endothelial cell membranes with IC50 of 21 nM.
    AVE 0991 sodium salt
  • HY-N0114A
    (±)-Evodiamine 518-18-3 99.74%
    (±)-Evodiamine, a quinazolinocarboline alkaloid, is a Top1 inhibitor. Evodiamine exhibits anti-inflammatory, antiobesity, and antitumor effects. (±)-Evodiamine inhibits the proliferation of a wide variety of tumor cells by inducing their apoptosis.
    (±)-Evodiamine
  • HY-P1271A
    Catestatin TFA 99.10%
    Catestatin TFA is a 21-amino acid residue, cationic and hydrophobic peptide. Catestatin TFA is an endogenous peptide that regulates cardiac function and blood pressure. Catestatin TFA is a non-competitive nicotinic antagonist acting through nicotinic acetylcholine receptors (nAChRs) to inhibit catecholamine release.
    Catestatin TFA
  • HY-P1298A
    Sauvagine TFA 98.76%
    Sauvagine TFA, a 40-amino-acid neuropeptide from the skin of the frog, is a mammalian CRF agonist. Sauvagine TFA is effective at releasing ACTH from rat pituitary cells. Sauvagine TFA possesses a number of pharmacological actions on diuresis, the cardiovascular system and endocrine glands.
    Sauvagine TFA
  • HY-P99794
    Osocimab 2056878-75-0 98.00%
    Osocimab (BAY 1213790), an anti-FXIa antibody (Ki=2.4 nM; EC50=0.2 nM). FXI inhibition may reduce the risk of thrombosis. Osocimab inhibits thrombin generation, and prolongs activated partial thromboplastin time. Osocimab exhibits anticoagulant effects.
    Osocimab
  • HY-105239A
    Selepressin acetate 98.77%
    Selepressin (FE 202158) acetate is a selective vasopressin V1A receptor agonist. Selepressin acetate is a potent vasopressin. Selepressin acetate can be used in the study of septic shock.
    Selepressin acetate
  • HY-17504BS
    Rosuvastatin-d3 sodium 1279031-70-7 98.19%
    Rosuvastatin-d3 (sodium) is deuterium labeled Rosuvastatin.
    Rosuvastatin-d3 sodium
  • HY-W095200
    GPR109 receptor agonist-2 957129-38-3 99.08%
    GPR109 receptor agonist-2 (Compound 5) is a selective GPR109a agonist with a pEC50 of 5.53.
    GPR109 receptor agonist-2
  • HY-W181102
    NFAT Inhibitor-2 422546-87-0 98.02%
    NFAT Inhibitor-2 is a potent inhibitor of calcineurin NFAT signalling. Calcineurin is a serine/threonine protein phosphatase regulated by Ca2+ and calmodulin. NFAT Inhibitor-2 has the potential for the research of inflammatory disease, an autoimmune disorder, a cardiovascular disease, a neurodegenerative disease, a disease occurring with uncontrolled cell proliferation and/or differentiation, an angiogenesis-related disease, an allergy, anaphylaxis and alopecia (extracted from patent WO2016207212A1, compound 17).
    NFAT Inhibitor-2
  • HY-23093
    L-Aspartyl-L-phenylalanine 13433-09-5 ≥98.0%
    L-Aspartyl-L-phenylalanine is a metabolite of aspartame that can inhibit angiotensin converting enzyme (ACE) purified from rabbit lungs with a Ki of 11 μM.
    L-Aspartyl-L-phenylalanine
  • HY-D0850
    Tartaric acid disodium dihydrate 6106-24-7 ≥98.0%
    Tartaric acid disodium dehydrate (L-(+) -tartaric acid) is an orally active weak organic acid that can be isolated from grapes. Tartaric acid disodium dehydrate has vasodilatory and antihypertensive effects. Tartaric acid disodium dehydrate can be used as flavorings and antioxidants in a range of foods and beverages. Tartaric acid disodium dehydrate can be used in laser frequency doubling and optical limiting applications.
    Tartaric acid disodium dihydrate
  • HY-139427
    3-Methylglutaconic acid 5746-90-7 99.60%
    3-Methylglutaconic acid is the major metabolites accumulating in 3-Methylglutaconic aciduria (MGTA). 3-Methylglutaconic acid can induce lipid oxidative damage and protein oxidative. 3-Methylglutaconic acid decreases the non-enzymatic antioxidant defenses in cerebral cortex supernatants to elicit oxidative stress in the cerebral cortex. 3-Methylglutaconic acid can be used for brain damage disease research.
    3-Methylglutaconic acid
  • HY-18600A
    Azimilide dihydrochloride 149888-94-8 98.91%
    Azimilide (NE-10064) dihydrochloride is a class III antiarrhythmic compound, inhibits I(Ks) and I(Kr) in guinea-pig cardiac myocytes and I(Ks) (minK) channels expressed in Xenopus oocytes.
    Azimilide dihydrochloride
  • HY-N1428R
    Citric acid (standard) 77-92-9
    Citric acid (Standard) is the analytical standard of Citric acid. This product is intended for research and analytical applications. Citric acid is a natural preservative and food tartness enhancer. Citric acid induces apoptosis and cell cycle arrest at G2/M phase and S phase in HaCaT cells. Citric acid cause oxidative damage of the liver by means of the decrease of antioxidative enzyme activities. Citric acid causes renal toxicity in mice.
    Citric acid (standard)
  • HY-106591A
    4-Vinylcyclohexene dioxide 106-87-6 ≥98.0%
    4-Vinylcyclohexene dioxide is a metabolite of 4-vinylcyclohexene that can specifically destroy oocytes in primordial and primary follicles of rats and mice. 4-Vinylcyclohexene dioxide induces apoptosis in rat cells is associated with activation of a caspase-mediated cascade.
    4-Vinylcyclohexene dioxide
  • HY-70035
    Otamixaban 193153-04-7 98.25%
    Otamixaban(FXV673) is a potent (Ki = 0.5 nM), selective, rapid acting, competitive and reversible fXa inhibitor that effectively inhibits both free and prothrombinase-bound fXa.
    Otamixaban
  • HY-100771
    PCC0208009 1668565-74-9 99.08%
    PCC0208009 is a potent IDO inhibitor with an IC50 value of 4.52 nM in HeLa cell. PCC0208009 alleviates neuropathic pain and comorbidities by regulating synaptic plasticity of anterior cingulate cortex (ACC) and amygdala .
    PCC0208009
  • HY-19321
    PF-06282999 1435467-37-0 99.02%
    PF-06282999 is a potent and selective myeloperoxidase inhibitor which is potential useful for the treatment of cardiovascular diseases.
    PF-06282999
  • HY-100882
    ONO-7300243 638132-34-0 98.46%
    ONO-7300243 is a novel, potent lysophosphatidic acid receptor 1 (LPA1) antagonist with IC50 of 0.16 μM.
    ONO-7300243
  • HY-106004
    Zamicastat 1080028-80-3 ≥98.0%
    Zamicastat (BIA 5-1058) is a dopamine β-hydroxylase (DBH) inhibitor and can cross the blood-brain barrier (BBB) to cause central as well as peripheral effects. Zamicastat is also a concentration-dependent dual P-gp and BCRP inhibitor with IC50 values of 73.8 μM and 17.0 μM, respectively. Zamicastat reduces high blood pressure.
    Zamicastat
Cat. No. Product Name / Synonyms Application Reactivity